Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01890590 · ClinicalTrials.gov registry record · NA

A Phase II Study of Cyberknife Radiosurgery for Renal Cell Carcinoma

A NA study of Renal Cell Carcinoma, sponsored by Beth Israel Deaconess Medical Center.

Recruiting
Registry status
NA
Development phase
46
Enrollment target
1
Study location

NCT01890590 is a NA study of Renal Cell Carcinoma that is actively recruiting participants, run by Beth Israel Deaconess Medical Center. The registered enrollment target is 46 participants, below the 243-participant average among 121 other Renal Cell Carcinoma trials with a reported enrollment target (81% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01890590, a NA study of Renal Cell Carcinoma, is actively recruiting participants, sponsored by Beth Israel Deaconess Medical Center.

RECRUITING
Registry status
NA
Development phase
46 participants
Enrollment target
1
Study location

Study Summary

CyberKnife Based Radiosurgery is a way to deliver large doses of radiation very accurately to a tumor. The ability of this technology to minimize radiation dose to organs adjacent to the target tumor allows a high dose to be delivered to the tumor, thus potentially increasing the efficacy of radiation treatment. Currently, radiosurgery is commonly used for brain metastases, Stage I lung cancer, spine tumors, and localized prostate cancer. The purpose of this protocol is to evaluate the role of Radiosurgery for the treatment of clinically localized primary renal cell carcinoma.

Conditions Studied

Interventions

  • DEVICE CyberKnife

Study Locations (1)

Massachusetts

  • Beth Israel Deaconess Medical Center - Boston

Trial Details

FieldValue
Enrollment Target 46 participants
Start Date 2013-07
Est. Completion 2025-03
Phase NA

What the Registry Record Tells You About NCT01890590

The ClinicalTrials.gov registry entry for NCT01890590 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 46 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 243-participant average among 121 other Renal Cell Carcinoma trials with a reported enrollment target (81% lower). The listed sponsor is Beth Israel Deaconess Medical Center, which has 488 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Renal Cell Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which CyberKnife is the first listed.

NCT01890590 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.

Frequently Asked Questions

What is clinical trial NCT01890590 about?

NCT01890590 is a clinical study titled "A Phase II Study of Cyberknife Radiosurgery for Renal Cell Carcinoma". CyberKnife Based Radiosurgery is a way to deliver large doses of radiation very accurately to a tumor. The ability of this technology to minimize radiation dose to organs adjacent to the target tumor allows a high dose to be delivered to the tumor, thus potentially increasing the efficacy of radiati...

What is the current status of trial NCT01890590?

This trial is currently recruiting. It is a NA study. The enrollment target is 46 participants. The study started on 2013-07. Estimated completion is 2025-03.

What conditions does trial NCT01890590 study?

This clinical trial studies the following conditions: Renal Cell Carcinoma.

What interventions are being tested in trial NCT01890590?

The interventions under investigation include: CyberKnife (DEVICE).

Who is sponsoring clinical trial NCT01890590?

This trial is sponsored by Beth Israel Deaconess Medical Center, which has 488 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01890590 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Renal Cell Carcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.